Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY: GSK )

33.09 -0.66 (-1.96%)
Official Closing Price Updated: 7:00 PM EST, Jan 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
36 37 Next >
GSK Touts Encouraging Data From Mid-Stage Tuberculosis Program In Drug-Susceptible Patients
Via Benzinga
GSK Limits Second-Line Maintenance Use Of Its Ovarian Cancer Drug To Some Populations
Via Benzinga
Europe Approves Sanofi, GSK's Beta Variant Adapted COVID Shot As Booster
Via Benzinga
Biogen, Seagen Name New CEOs — But One Biotech Stock Crumbles
Biogen jumped after naming Christopher Viehbacher its CEO. David Epstein will take over at Seagen. 
Via Investor's Business Daily
GSK's Conditionally Approved Blood Cancer Drug Fails On Progression-Free Survival Goal Over Standard Care
Via Benzinga
Week in Review: CBC Plans $137 Million Shanghai Biopharma Complex
Deals, financings, trials and approvals in Chinese biotech/biopharma this week. 
Via Talk Markets
Why Vir Biotechnology Jumped Nearly 19% Today
A COVID-19 partnership with a major drugmaker is producing more fruit than expected. 
Via The Motley Fool
Citing Efficacy, GSK Stops Two Pivotal UTI Antibiotic Trials Early
Via Benzinga
GSK Surges As Shingles Vaccine Drives Commanding Third-Quarter Beat
Shingrix and specialty medicines helped drive GSK's third-quarter growth. 
Via Investor's Business Daily
Vir Obliterates Quarterly Sales Expectations As Covid Drug Delivers Triple-Digit Growth
Sales of Vir Biotechnology and GSK's Covid antibody almost tripled sales estimates. 
Via Investor's Business Daily
Moderna's Earnings Collapsed. Time to Sell?
This drugmaker's bottom line fell down a deep hole in the third quarter and investors want to know if it's time to run for the hills. 
Via The Motley Fool
Downsizing At Twitter After Musk Takeover, Big Pharma Chains To Pay $14B In Opioid Claims, Tesla Shutters 1st Showroom In China: Top Stories Wednesday, Nov. 02
Reuters 
Via Benzinga
GSK Lifts Annual Outlook After Robust Vaccines, Specialty Medicine Sales In Q3
Via Benzinga
Recap: GSK Q3 Earnings
GSK (NYSE:GSK) reported its Q3 earnings results on Wednesday, November 2, 2022 at 05:00 AM. Here's what investors need to know about the announcement. Earnings GSK beat estimated earnings by 15.63%,... 
Via Benzinga
GSK's Debt Overview
Over the past three months, shares of GSK Inc. (NYSE:GSK) decreased by 16.74%. Before having a look at the importance of debt, let's look at how much debt GSK has. 
Via Benzinga
GSK Pulls Plug On Late-Stage Asset Under Development For Rheumatoid Arthritis
Via Benzinga
GSK One Step Closer To FDA Approval For Anemia Drug For Dialysis Patients
Via Benzinga
Earnings This Week: AMD, BP And PayPal
Find out what to expect from this week's earnings calendar. 
Via Talk Markets
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
GSK Q3 2022 Earnings Conference Call On November 2, 2022 At 08:00 AM ET
GSK (NYSE:GSK) will host a conference call at 08:00 AM ET on November 2, 2022, to discuss Q3 2022 earnings results. How to Attend GSK (GSK) Conference Call Follow this link to access the live webcast. 
Via Benzinga
Is Merck Moving Toward Another Blockbuster Drug Launch?
Merck will soon share its positive phase 3 clinical trial results for a rare disease drug candidate at an upcoming event. 
Via The Motley Fool
GSK Transfers Cell Therapy Program Rights To Adaptimmune, Terminates Second Cell Therapy Pact In A Day
Via Benzinga
GSK Walks Away From T-Cell Therapy Pact With Lyell Citing Strategic Actions
Via Benzinga
3 Things the Smartest Investors Know About This Beaten-Down Stock
Moderna's story may just be beginning. 
Via The Motley Fool
GSK Plc (NYSE:GSK) Investor Alert: Investigation over Potential Wrongdoing
San Diego, CA -- (SBWIRE) -- 10/21/2022 -- An investigation was announced on behalf of investors in NYSE:GSK shares over potential breaches of fiduciary duties by certain officers and directors at GSK... 
Via SBWire
Children's Hospitals Strained After Climbing Cases In Respiratory Illnesses In Kids
Physicians are reporting a sharp increase in cases of the respiratory syncytial virus (RSV), creating capacity issues in several children's hospitals in the U.S. before the typically busier winter... 
Via Benzinga
Peering Into GSK's Recent Short Interest
GSK's (NYSE:GSK) short percent of float has risen 12.86% since its last report. The company recently reported that it has 15.83 million shares sold short, which is 0.79% of all regular shares that are... 
Via Benzinga
Boston University's COVID-19 Created In Lab Research Comes Under Scrutiny
Boston University created an artificial form of COVID-19 in a laboratory. Now, U.S. health officials have launched an inquiry into a controversial study. The Boston University research was designed to... 
Via Benzinga
7 Quality Stocks Selling at a Discount as Q4 Kicks Off
Stocks may have just entered a bull market, so bullish investors should look for quality stocks selling at a discount to buy before a rally. 
Via InvestorPlace
This Addiction Drug Shows Some Potential Against Long COVID Symptoms
Researchers are working on cures for long COVID. With some success, naltrexone has been used to treat pain, fatigue, and brain fog months after a coronavirus infection. 
Via Benzinga
< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
36 37 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.